QIBA Dynamic Susceptibility Contrast (DSC) Biomarker Committee (BC) Call
Wednesday, October 10, 2018 at 11 AM (CT)
Call Summary

Moderator: Dr. Wu

Participants
Bradley Erickson, MD, PhD (Co-Chair)   Edward Jackson, PhD   Mark Shiroishi, MD   Joe Koudelik
Ona Wu, PhD (Co-Chair)  Nancy Obuchowski, PhD

RSNA

DSC Profile Update
- RSNA staff to email Profile Google link to all DSC BC members:
  https://drive.google.com/open?id=0B9fMpfGBAByMfnY5UG83bXJKUnc0dGNBTVFnX0Mxclg0LWRsVkkxeFRWU3RRSF1VWlZN0k
- Dr. Wu provided an update on the DSC Profile Claim development process
- The Claims are based on estimates of perfusion AUC-TN coefficient of variation (wCV) for regions of interest in this size range located in enhancing tumor or normal tissue
- Discussion occurred regarding the soundness of the phantom study test-retest data
- During the scanning process, it was discovered that a couple of days is needed between scans
- Suggestion to request results from authors of the paper upon which the Claims are based; subsequently, the Coefficient of Variation (wCV) and repeatability variation can be calculated
- Sample size:
  - 33 participants with double data acquisition
  - Dr. Obuchowski confirmed that the sample size was statistically adequate

- Discussion on confidence interval occurred:
  - Profile currently indicates reproducibility coefficient within enhancing tumor of less than 86%
  - Currently, clinical performance target indicated in the Profile is to achieve a 95% confidence interval for the AUC-TN true change in enhancing tumor tissue if the measured change is 86% or more and in normal tissue if the measured change is 111% or more
  - It was recommended that the group decide which value is the most appropriate; while 86% is acceptable, choosing a middle value is not required and providing a range may be considered
  - A confidence interval was determined as 1.44 – 2.34; any value within this range was deemed appropriate by Dr. Obuchowski for this Profile

- Dr. Wu to send three references describing study analysis approaches to Dr. Shiroishi for cross-checking
- To make sure the recommended sequence is appropriate, the Profile user may scan a phantom to determine whether there is linear correlation with the planned protocol (linearity assessment)
  - Ideally, the slope should be “1,” but it is not necessary
  - It was advised that this should not be a Claim, but rather an assessment procedure the Profile user needs to perform: “Shall perform periodic system QA using QIBA-NIST DSC phantom which includes assessment of temporal SNR and linearity”
  - Once the assessment has been performed, the patient would be ready to be scanned
  - Dr. Wu will work on this section
• Dr. Erickson to work on Section 2: Clinical Context and Claims
• Dr. Shiroishi to review the referenced articles and ensure consistency of data sets
• Volunteers were requested to proofread Sections 1 - 3 for errors prior to next call
• Dr. Erickson to use reproducibility of data results from his paper to complete Table 1 in Section 2.2: Clinical Interpretation Discussion
• Discussion on “tumor size” in Section 3.11.1: Image QA Discussion; Dr. Wu to make text modifications based on “enhancing tumor area”
• “Image reconstruction” bullet in 3.12: Image Distribution to be removed
• Dr. Erickson to make edits to Section 3.14: Image Interpretation

QIBA Working Meeting and Meet-the-Experts Sessions at RSNA 2018
• All are encouraged to RSVP for the QIBA Working Meeting on Wednesday, November 28th.
• All are invited to volunteer for the poster Meet-the-Expert session times

Poster Preparation for RSNA 2018
• DSC-MRI will be sharing a poster with the DCE-MRI Biomarker Committee
• Due to the growing number of BCs, 5 posters have been allocated among the 8 MR BCs for 2018

Next DSC BC Call: Wednesday, November 21, 2018 at 11 AM CT

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.